检索结果 - Carlos Gomez‐Roca

Refine Results
  1. 1
    Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study

    Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study 由 Carlos Gomez‐Roca, Jean‐Pierre Delord, Caroline Robert, Manuel Hidalgo, Roger von Moos, Ana Arance, Elena Élez, Daniela Michel, Abdelkader Seroutou, Tim Demuth, Josep Tabernero

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?

    Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities? 由 Sophie Postel‐Vinay, Carlos Gomez‐Roca, L Rhoda Molife, B. Anghan, Antonin Lévy, Ian Judson, Johann S. de Bono, Jean‐Charles Soria, Stan B. Kaye, Xavier Paolettí

    出版 2011
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

    Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials 由 Charles Ferté, Marianna Fernandez, Antoine Hollebecque, Serge Koscielny, Antonin Lévy, Christophe Massard, Rastislav Balheda, Brian M. Bot, Carlos Gomez‐Roca, Clarisse Dromain, Samy Ammari, Jean‐Charles Soria

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

    Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628 由 Anastasios Stathis, Emanuele Zucca, Mohamed Békradda, Carlos Gomez‐Roca, Jean‐Pierre Delord, Thibault De La Motte Rouge, Emmanuelle Uro‐Coste, Filippo de Braud, Giuseppe Pelosi, Christopher A. French

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites

    Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites 由 Carlos Gomez‐Roca, Christophe M. Raynaud, Frédérique Penault‐Llorca, Olaf Mercier, Frédéric Commo, Luc Morat, Laure Sabatier, Philipe Dartevelle, E. Taranchon, Benjamin Besse, Pierre Validire, Antoîne Italiano, Jean‐Charles Soria

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

    Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial 由 Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan, Carlos Gomez‐Roca, Jean‐Philippe Metges, Antoine Adenis, Simon Pernot, C. Bellera, Michèle Kind, Céline Auzanneau, François Le Loarer, Isabelle Soubeyran, Alban Bessede, Antoîne Italiano

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients

    Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patie... 由 Tania Crombet, Marta Osorio, Teresa Cruz, Carlos Gómez Roca, Ramón del Castillo, Rosa Mon, Normando Iznaga-Escobar, René Figueredo, James Koropatnick, Enrique Renginfo, Eduardo Fernández, Daniel Esteban Pineda Alvarez, Olga Torres, Mayra Ramos, I. Leonard, Rolando Pérez, Agustín Lage

    出版 2004
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

    Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti... 由 Paolo A. Ascierto, Petri Bono, Shailender Bhatia, Ignacio Melero, Marta Nyakas, Inge Marie Svane, James Larkin, Carlos Gomez‐Roca, Dirk Schadendorf, R. Dummer, Aurélien Marabelle, Christoph Höeller, Mark Maurer, Christopher Harbison, Priyam Mitra, Satyendra Suryawanshi, Kent Thudium, Eva Muñoz‐Couselo

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours

    LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours 由 Zarnie Lwin, Carlos Gomez‐Roca, Esma Saâda-Bouzid, Eduardo Yáñez, Federico Longo Muñoz, S-A. Im, Eduardo Castañón, Hélène Senellart, Donna M. Graham, Martin H. Voss, Mark Doherty, Juanita Lopez, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Hyun Cheol Chung

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

    Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 由 Patrick A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster, Michael J. Pishvaian, Emilie M.J. van Brummelen, Roger B. Cohen, Carlos Gomez‐Roca, Samuel Ejadi, Mark N. Stein, Emily Chan, Matteo Simonelli, Anne Morosky, Sanatan Saraf, Kenneth Emancipator, Minori Koshiji, Jaafar Bennouna

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

    Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia 由 Norbert Vey, Jacques Delaunay, Giovanni Martinelli, Walter Fiedler, Emmanuel Raffoux, Thomas Prébet, Carlos Gomez‐Roca, Cristina Papayannidis, Maxim Kebenko, Peter Paschka, R D Christen, Ernesto Guarin, Ann‐Marie Bröske, Monika Baehner, Michael Brewster, Antje‐Christine Walz, Francesca Michielin, Valeria Runza, Valérie Méresse, Christian Récher

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

    Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma 由 Bert H. O’Neil, John M. Wallmark, David Lorente, Elena Élez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina A. Piha‐Paul, Mark N. Stein, Albiruni R. Abdul Razak, Katia Dotti, Armando Santoro, Roger B. Cohen, M. Gould, Sanatan Saraf, Karen Stein, Sae‐Won Han

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin 由 Raffit Hassan, Christine Alewine, Idrees Mian, Anna Spreafico, Lillian L. Siu, Carlos Gomez‐Roca, Jean‐Pierre Delord, Antoîne Italiano, Ulrik Lassen, Jean‐Charles Soria, Rastilav Bahleda, Anish Thomas, Seth M. Steinberg, Cody J. Peer, William D. Figg, Gerhard Niederfellner, Valérie Meresse Naegelen, Ira Pastan

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

    Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors 由 Neeltje Steeghs, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg, Morten Mau‐Sørensen, Debbie Robbrecht, Josep Tabernero, Samreen Ahmed, María E. Rodríguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero

    出版 2024
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics

    Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma pr... 由 Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola‐Jade Palmieri, Jean Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, C. Bellera, Antoine Adenis, Carlos Gomez‐Roca, Philippe A. Cassier, Antoine Hollebecque, Coralie Cantarel, Michèle Kind, Isabelle Soubeyran, Lucile Vanhersecke, Alban Bessede, Antoîne Italiano

    出版 2024
    获取全文
    Carta
    加到收藏夹
    Saved in:
  16. 16
    PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells

    PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells 由 Camille-Charlotte Balança, Anna Salvioni, Clara‐Maria Scarlata, Marie Michelas, Carlos Martínez-Gómez, Carlos Gomez‐Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Fréderic Pont, Gwénaël Ferron, Laurence Gladieff, S. Vergèz, Agnès Dupret‐Bories, Eliane Mery-Lamarche, Philippe Rochaix, Jean‐Jacques Fournié, Jean‐Pierre Delord, Christel Devaud, Alejandra Martínez, Maha Ayyoub

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

    Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy... 由 Paolo A. Ascierto, Hao Tang, Sonia Dolfi, Marta Nyakas, Inge Marie Svane, Eva Muñoz‐Couselo, Jean‐Jacques Grob, Carlos Gomez‐Roca, Vanna Chiarion‐Sileni, Katriina Peltola, James Larkin, Ignacio Melero, Margaret K. Callahan, Reinhard Dummer, Patrick Djidel, Deepti Warad, Diane Reusser-Wolf, Evan J. Lipson, Charlie Garnett‐Benson

    出版 2025
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant Melanoma

    Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant Melanoma 由 Jean‐Pierre Delord, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Kudchakar, Amit Mahipal, Yasuhide Yamada, Ryan J. Sullivan, Ana Arance, Richard Kefford, Matteo S. Carlino, Manuel Hidalgo, Carlos Gomez‐Roca, Daniela Michel, Abdelkader Seroutou, Vassilios Aslanis, Giordano Caponigro, Darrin D. Stuart, Laure Moutouh–de Parseval, Tim Demuth, Reinhard Dummer

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors

    Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors 由 David Olmos, Roger A’Hern, Silvia Marsoni, Rafael Morales, Carlos Gomez‐Roca, Jaap Verweij, Emile E. Voest, Patrick Schöffski, Joo Ern Ang, Nicolas Penel, Jan H.M. Schellens, Gianluca Del Conte, André T. Brunetto, T.R. Jeffry Evans, Richard H. Wilson, Elisa Gallerani, Ruth Plummer, Josep Tabernero, Jean‐Charles Soria, Stan B. Kaye

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging

    Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simulta... 由 Anne Laprie, S. Ken, Thomas Filleron, V. Lubrano, L. Vieillevigne, Fatima Tensaouti, I. Catalaa, S. Boetto, Jonathan Khalifa, Justine Attal, G. Peyraga, Carlos Gomez‐Roca, Emmanuelle Uro‐Coste, G. Noël, G. Truc, Marie‐Pierre Sunyach, Nicolas Magné, M. Charissoux, S. Supiot, V. Bernier, Muriel Mounier, Muriel Poublanc, Amandine Fabre, Jean‐Pierre Delord, Elizabeth Cohen‐Jonathan Moyal

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: